FAQs & How to use this site
Home | About Us | Contact Us
The Front Line
The Front Line: Charles D. Blanke, MD, SWOG Chair

PREVIOUS POSTS November 2017

October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 JUNE 2016 MAY 2016 APRIL 2016 MARCH 2016 FEB 2016 JAN 2016 DEC 2015 NOV 2015 OCT 2015 SEP 2015 AUG 2015 JUL 2015 JUN 2015 MAY 2015 APR 2015 MAR 2015 FEB 2015 JAN 2015 DEC 2014 NOV 2014 OCT 2014 SEP 2014 AUG 2014 JUL 2014 JUN 2014 MAY 2014 APR 2014 MAR 2014 FEB 2014 JAN 2014 DEC 2013 NOV 2013 OCT 2013 SEP 2013 AUG 2013 JUL 2013

SWOG at ASCO 2014

May 23, 2014 - As many of us prepare to head to Chicago next week for the annual ASCO meeting, here's a quick look at some of the many ways SWOG is well-represented, in a variety of ways, at that event.

To start, 14 SWOG-led studies will be presented, while at least 10 others cover intergroup research to which SWOG investigators made major contributions.

This group of two dozen abstracts features three plenary presentations, one reporting on an ECOG-led trial with significant SWOG input, one a joint analysis of studies by the IBCSG, and one delivering results of the co-led CALGB/SWOG 80405 study, which pitted bevacizumab against cetuximab as an accompaniment to chemotherapy for patients with KRAS wild-type metastatic colorectal cancer.

Also among the two dozen are seven other oral presentations and 14 posters. Oral presentations on SWOG studies include the following:

  • The results of the S0230 Prevention of Early Menopause Study (POEMS), which added goserelin to chemotherapy to help preserve fertility and ovarian function in younger women treated for breast cancer.
  • S0033, a report detailing a surprisingly high fraction of long-term survivors in patients with advanced GIST and imatinib treatment.
  • Results from S0925, which compared androgen-deprivation with and without cixutumumab, for patients with metastatic castration-resistant prostate cancer.

But this is only a start.

A number of investigators sit on the ASCO Board of Directors or committees involved with the annual meeting. We also have at least 44 of our members contributing to educational sessions or other panels. Here are a few of those sessions being chaired or including discussion by SWOG investigators (in roughly chronological order):

  • Ian M. Thompson, SWOG Genitourinary Committee Chair - Updates in Prostate Cancer Risk & Prevention (Fri 4:30 PM)
  • Martin J. Edelman - The Current Status of Therapy for Non-Small Cell Lung Cancer (Fri 4:30 PM)
  • Supriya Mohile - Why Functional Age Matters: Care for Older Patients with Prostate and Bladder Cancer (Fri 4:30 PM)
  • Frederick Appelbaum - Management of Acute Myeloid Leukemia in the Genomic Era (Sat 8 AM)
  • Anthony Back - Burnout in Health Care Professionals: Improving the Care You Provide by Caring for Your Mental and Physical Well-being (Sat 1:15 PM)
  • Mario Sznol - Practical Considerations in the Design of Clinical Trials of Targeted Therapies and Immunotherapy (Sat 1:15 PM)
  • Ronald L. Coleman - Selecting the Best Therapy for Recurrent Ovarian Cancer: Progress in Response Prediction over the Last 50 Years (Sat 4:45 PM)
  • Laurie E. Gaspar - Tools for the Best Outcomes in the Management of Brain Metastases (Sun 11:30 AM)
  • Christopher Logothetis - Rare Genitourinary Tumors: Lethal Prostate Cancer Variants, Non-Clear Cell Renal Cell Carcinoma, and Penile Cancer (Sun 11:30 AM)
  • Scott N. Gettinger - Understanding, Exploring, and Looking at New and Future Developments in Non-Small Cell Lung Cancer Immunotherapy (Sun 4:45 PM)
  • Shreyaskumar Patel - 50 Years of Advances in Sarcoma (Mon 9:45 AM)
  • Susan M. O'Brien, SWOG Executive Officer - Chronic Lymphocytic Leukemia Therapy: An Update on Front-Line and Novel Therapies (Mon 1:15 PM)
  • Lee Ellis, SWOG Vice-Chair for Translational Medicine - The Angiogenesis Dilemma (Mon 1:15 PM)

I am truly proud of our members. I realize this list is likely not exhaustive, and I apologize to anyone I left off. I do hope this gives you a picture of our vibrant research organization, contributing mightily to medical science and dedicated to improving the lives of cancer patients. I look forward to seeing many of you in Chicago.


SWOG Logo Disclaimer | Copyright ©1999-2017 SWOG. All rights reserved.
Design and Hosting by nuMedia
SWOG is FISMA CertifiedSWOG is FISMA Certified